Report: UCB: Pipeline, Products, Performance, Potential TOC

Principal Operating Results
Breaking News
Latest Results
EXECUTIVE SUMMARY
- Introduction
  - Current Growth Drivers
  - Key Late-Stage Products
  - Key Early-Stage Products
- Financial Performance 2005
  - Sales and Market Position
  - Income
    - Operating Profit By Business Segment
  - Expenditure
    - Capital Expenditure
    - Investments By Business Area
    - R&D Expenditure
    - R&D Expenditure By Business Area
  - Divisional Performance
    - Consolidated Turnover By Business Area
  - Geographic Performance
    - Total Revenues By Geographic Area
    - Net Biopharmaceutical Sales By Geographical Area
- Company Strategy
  - Mergers, Acquisitions and Divestitures
    - Acquisitions
    - Divestitures
  - Key Agreements
  - Production
  - Employees
    - Employees By Geographical Area (Year End)
- Product / R&D Overview
  - Key Products
    - Recent Product Launches
    - Recent Product Approvals
  - R&D Strategy
    - Key R&D Projects
  - R&D Pipeline Overview
    - Discontinued R&D projects
  - Sales Forecasts
- Conclusions/Outlook
PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT
- Sales Of Major Biopharmaceutical Products
- R&D Pipeline
- Immuno-allergology - Products
  - Major Launched Products
  - Arthrotec
  - Dipentum
  - Mistabron/Mucofluid
  - Theo 24
  - Xyzal/Xusal
    - Mode of Action
    - Sales
    - Key Markets/Indications
    - Further Development
    - Patents/Licensees
    - Competitor Products
    - Sales Forecast
  - Zyrtec/Reactine
    - Mode of Action
    - Licensees
    - Competitor Products
    - Patents/Generic Competition
    - Sales Forecast
- Immuno-allergology - R&D
  - AZD8955
  - Cimzia
    - Clinical Trial Results
    - Clinical Trial Results - Psoriasis
  - Efletirizine (UCB28754)
  - Epratuzumab
- Immuno-Allergology - Summary
  - Growth Potential
  - Limiting Factors
- Central Nervous System - Products
  - Major Launched Products
  - Atarax
    - Sales Forecast
  - Keppra
    - Mode of Action
    - Sales
    - Key Markets/Indications
    - Further Development
    - Treatment Guidelines/Reimbiursement
    - Competitor Products
    - Generic Competition
    - Sales Forecast
    - Clinical Trial Results - Brain Tumours
    - Clinical Trial Results - Myoclonic Seizures
    - Clinical Trial Results - Bipolar And Aggressive Disorders
    - Clinical Trial Results - Parkinson' s Disease
    - Clinical Trials Results - Pain Control
    - Phase IV Programme
  - Longifene
  - Metadate CD/Equasym XL
    - Sales
    - Key Markets/Indications
    - Competitor Products
    - Sales Forecast
  - Nootropil
    - Sales
    - Key Markets/Indications
    - Sales Forecast
  - Postafene
  - Xyrem
    - Key Markets/Indications
    - Further Development
    - Clinical Trial Results
- Central Nervous System - R&D
  - Brivaracetam (UCB34714)
  - CDP323
  - Seletracetam (UCB44212)
  - UCB 106607
- Central Nervous System - Summary
- Cardiovascular - Products
  - Cinalong
  - Rocornal
- Gastrointestinal - Products
  - Stogar
    - Sales Forecast
- Oncology - R&D
  - CDP791
  - CMC544
- Others - Products
  - Major Launched Products
  - Balsoclase/Sedotussin/Toclase
  - Biofenac
  - Bup-4
    - Sales Forecast
  - Butenafine
  - Catabex
  - Duratuss
  - Kentera
    - Key Markets/Indications
  - Lortab
    - Sales Forecast
  - Tussionex
    - Sales Forecast
APPENDIX 1 - FINANCIAL PERFORMANCE
- Full Year Results 2005
APPENDIX 2 - KEY AGREEMENTS
- Actelion Ltd
  - 17th November 2005
- Adams Respiratory Therapeutics
  - 24th May 2006
- Amgen
  - 17th May 2002
  - 19th September 2006
- AstraZeneca
  - 9th October 1995
  - 1st March 1999
- Biogen Idec Inc
  - 2nd October 2006
- BioInvent International AB
  - 14th March 2002
  - July 2006
- Crucell NV and DSM Biologics
  - 14th March 2006
- ImClone Systems Inc
  - 15th August 2005
- Immunomedics Inc
  - 10th May 2006
- Lonza Biologics Ltd
  - 14th July 2003
  - 13th May 2005
- Merck & Co
  - 24th September 2003
- Nektar Therapeutics
  - 18th October 2002
- Orphan Medical
  - 30th October 2003
  - 21st March 2005
  - 3rd October 2006
- Pfizer
  - 23rd July 2002
  - Discontinued agreement
- Recordati
  - 24th April 2006
- sanofi-aventis
  - 25th September 2006
- Sepracor Inc
  - 1st June 1999
  - 23rd February 2006
- Verus Pharmaceuticals Inc
  - 21st August 2006
- Watson Pharmaceuticals Inc
  - 24th September 2003
APPENDIX 3 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
APPENDIX 4 - KEY PHARMACEUTICAL
- SUBSIDIARIES / JOINT VENTURES
- Subsidiaries
- Joint Ventures
APPENDIX 5 - PRODUCT INDEX

Index of Tables

Principal Operating Results
Operating Profit By Business Segment
Investments By Business Area
R&D Expenditure By Business Area
Consolidated Turnover By Business Area
Total Revenues By Geographic Area
Net Biopharmaceutical Sales By Geographical Area
Employees By Geographical Area (Year End)
Recent Product Launches
Recent Product Approvals
Key R&D Projects
Sales Of Major Biopharmaceutical Products
R&D Pipeline
Major Launched Products
Major Launched Products
Major Launched Products

Index of Charts

Sales, Costs and Operating Income
Operating Profit By Business Segment
Investments By Business Area
R&D Expenditure By Business Area
Consolidated Turnover By Business Area
Total Revenues By Geographic Area. 2005
Net Biopharmaceutical Sales By Geographical Area, 2005
Employees By Geographical Area (Year End), 2005
Sales of Current Top Ten Products (2000A-2010E)
Top Selling Products, 2005
Xyzal Sales (2000A-2010E)
Zyrtec Sales (2000A-2010E)
Atarax Sales (2000A-2010E)
Keppra Sales (2000A-2010E)
Metadate Sales (2000A-2010E)
Nootropil Sales (2000A-2010E)
Stogar (2000A-2010E)
Bup-4 Sales (2000A-2010E)
Lortab Sales (2000A-2010E)
Tussionex Sales (2000A-2010E)
Sales, Costs and Operating Income
Profitability and Research Ratios
R&D Expenditure and Capital Expenditure
Current Assets, Liabilities and Ratio
Assets, Cash and Liquidity
Employees and Productivity

UCB: Pipeline, Products, Performance, Potential

Table of Contents

Index of Tables

Index of Charts